Baker Avenue Asset Management’s Vaxcyte PCVX Stock Holding History

Baker Avenue Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$772K	Buy	13,279 +136	+1%	+$7.39K	0.01%	367
2026 Q1	$764K	Hold	13,143	–	–	0.02%	324
2025 Q4	$606K	Hold	13,143	–	–	0.01%	333
2025 Q3	$473K	Hold	13,143	–	–	0.01%	362
2025 Q2	$427K	Sell	13,143 -1	-0%	-$33	0.01%	322
2025 Q1	$496K	Buy	13,144 +1	+0%	+$80	0.02%	296
2024 Q4	$1.08M	Hold	13,143	–	–	0.03%	229
2024 Q3	$1.5M	Sell	13,143 -500	-4%	-$45.1K	0.05%	208
2024 Q2	$1.03M	Hold	13,643	–	–	0.04%	221
2024 Q1	$932K	Sell	13,643 -137	-1%	-$9.49K	0.04%	219
2023 Q4	$865K	Hold	13,780	–	–	0.04%	218
2023 Q3	$703K	Hold	13,780	–	–	0.04%	232
2023 Q2	$688K	Hold	13,780	–	–	0.03%	225
2023 Q1	$516K	Sell	13,780 -30	-0.2%	-$1.27K	0.03%	257
2022 Q4	$662K	Buy	13,810 +30	+0.2%	+$1.18K	0.04%	213
2022 Q3	$331K	Hold	13,780	–	–	0.02%	278
2022 Q2	$300K	Hold	13,780	–	–	0.02%	266
2022 Q1	$333K	Hold	13,780	–	–	0.02%	254
2021 Q4	$328K	Buy	+13,780	New	+$320K	0.02%	256

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Baker Avenue Asset Management's PCVX Position: Q2 2026 in Review

Baker Avenue Asset Management increased its Vaxcyte (PCVX) stake by 1% in Q2 2026, buying an estimated $7.39K and bringing the position to 13,279 shares worth $772K. The position accounts for 0.01% of the portfolio, ranked #367.

Baker Avenue Asset Management first reported a position in PCVX in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.5M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Baker Avenue Asset Management held 13,279 shares of Vaxcyte worth $772K as of Q2 2026.
Baker Avenue Asset Management bought 136 Vaxcyte shares in Q2 2026, an estimated $7.39K.
Vaxcyte made up 0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #367 holding.
Baker Avenue Asset Management first reported a position in Vaxcyte in Q4 2021 and has held it in 19 quarters since.
Baker Avenue Asset Management's Vaxcyte position peaked at $1.5M in Q3 2024.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.